The Week Ahead – Big pharma to report earnings NEWS 02/08/2024 The Week Ahead – Big pharma to report earnings Weight-loss drug giants Novo Nordisk and Eli Lilly are both set to report earnings this week. On the macro front we look to Swiss CPI, US ISM services, and the next RBA decision, with Chinese inflation figures set to round out the week. Earnings come from Palantir, Lucid Group, Amgen, Caterpillar, Starbucks, AMD, Pinterest, Rivian, Uber, Novo Nordisk, Shopify, Etsy, Alibaba, Eli Lilly, Berkshire Hathaway. Find out more in the video below. Related News & Events Spotlight on Isabella Johnson, Finalto Relationship ManagerFinalto Relationship Manager Isabella Johnson tells us how she balances a complex workflow in a fast-paced industryRead MoreRethinking FX Risks and Opportunities in an Era of DisruptionIs it time for equity managers, FX traders & ordinary investors to rethink some of the received wisdom about currency risks?Read MoreInsights from iFX EXPO International with Paul JacksonFinalto Head of Sales Paul Jackson shares key insights and takeaways from iFX EXPO International 2025 held in CyprusRead MoreThe architecture of innovation: DeFi, AI and the path to regulationDecentralised finance, artificial intelligence and cryptocurrencies could transform finance. How will regulators and lawmakers respond?Read More View All
Spotlight on Isabella Johnson, Finalto Relationship ManagerFinalto Relationship Manager Isabella Johnson tells us how she balances a complex workflow in a fast-paced industryRead More
Rethinking FX Risks and Opportunities in an Era of DisruptionIs it time for equity managers, FX traders & ordinary investors to rethink some of the received wisdom about currency risks?Read More
Insights from iFX EXPO International with Paul JacksonFinalto Head of Sales Paul Jackson shares key insights and takeaways from iFX EXPO International 2025 held in CyprusRead More
The architecture of innovation: DeFi, AI and the path to regulationDecentralised finance, artificial intelligence and cryptocurrencies could transform finance. How will regulators and lawmakers respond?Read More